BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Møller S, Cour Sibbesen E, Madsen JL, Bendtsen F. Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease. Journal of Gastroenterology and Hepatology 2018;34:1093-9. [DOI: 10.1111/jgh.14470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Wu J, Xie F, Ji H, Zhang Y, Luo Y, Xia L, Lu T, He K, Sha M, Zheng Z, Yong J, Li X, Zhao D, Yang Y, Xia Q, Xue F. A Clinical-Radiomic Model for Predicting Indocyanine Green Retention Rate at 15 Min in Patients With Hepatocellular Carcinoma. Front Surg 2022;9:857838. [DOI: 10.3389/fsurg.2022.857838] [Reference Citation Analysis]
2 Köller A, Grzegorzewski J, Tautenhahn HM, König M. Prediction of Survival After Partial Hepatectomy Using a Physiologically Based Pharmacokinetic Model of Indocyanine Green Liver Function Tests. Front Physiol 2021;12:730418. [PMID: 34880771 DOI: 10.3389/fphys.2021.730418] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Grønbæk H, Møller HJ, Vilstrup H, Steensberg A, Jeppesen PB. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. EBioMedicine 2019;46:444-51. [PMID: 31326433 DOI: 10.1016/j.ebiom.2019.07.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vuille-Lessard É, Rodrigues SG, Berzigotti A. Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:253-89. [PMID: 33838850 DOI: 10.1016/j.cld.2021.01.005] [Reference Citation Analysis]
5 Voiosu AM, Wiese S, Goetze JP, Hartmann O, Voiosu T, Santos K, Møller S. Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis. Biomarkers 2021;:1-12. [PMID: 34964404 DOI: 10.1080/1354750X.2021.2024599] [Reference Citation Analysis]
6 Lin H, Zhou Y, Wang J, Wang H, Yao T, Chen H, Zheng H, Zhang Y, Ren E, Jiang L, Chu C, Chen X, Mao J, Wang F, Liu G. Repurposing ICG enables MR/PA imaging signal amplification and iron depletion for iron-overload disorders. Sci Adv 2021;7:eabl5862. [PMID: 34919434 DOI: 10.1126/sciadv.abl5862] [Reference Citation Analysis]
7 Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Semin Liver Dis 2020;40:240-55. [PMID: 32557480 DOI: 10.1055/s-0040-1708806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
8 Köller A, Grzegorzewski J, König M. Physiologically Based Modeling of the Effect of Physiological and Anthropometric Variability on Indocyanine Green Based Liver Function Tests. Front Physiol 2021;12:757293. [PMID: 34880776 DOI: 10.3389/fphys.2021.757293] [Reference Citation Analysis]
9 Gu J, Zhang E, Liang B, Zhang Z, Chen X, Huang Z. Effectiveness comparison of indocyanine green retention test with the cirrhotic severity scoring in evaluating the pathological severity of liver cirrhosis in patients with hepatocellular carcinoma and Child-Pugh grade A liver function. World J Surg Oncol 2020;18:79. [PMID: 32326968 DOI: 10.1186/s12957-020-01854-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
10 Zhang W, Hu B, Han J, Wang Z, Ma G, Ye H, Yuan J, Cao J, Zhang Z, Shi J, Chen M, Wang X, Xu Y, Cheng Y, Tian L, Wang H, Lu S. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Front Oncol 2021;11:747950. [PMID: 34737958 DOI: 10.3389/fonc.2021.747950] [Reference Citation Analysis]